Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
28 Jun 2022
28 Jun 2022
Historique:
received:
18
02
2022
accepted:
19
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
The O-acetyl (or acetate) derivative of the Aspidosperma alkaloid Jerantinine A (JAa) elicits anti-tumor activity against cancer cell lines including mammary carcinoma cell lines irrespective of receptor status (0.14 < GI
Identifiants
pubmed: 35785302
doi: 10.1021/acsomega.2c00997
pmc: PMC9244903
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21473-21482Informations de copyright
© 2022 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Biomacromolecules. 2011 May 9;12(5):1629-40
pubmed: 21446722
BMC Cancer. 2005 Feb 22;5:21
pubmed: 15723709
Metabolomics. 2020 Feb 29;16(3):33
pubmed: 32114632
Mol Cell. 2015 Jun 18;58(6):947-58
pubmed: 26091343
Br J Nutr. 2009 Apr;101(7):972-81
pubmed: 18755051
Cancer Lett. 2016 Jan 28;370(2):185-97
pubmed: 26515390
Invest New Drugs. 2014 Oct;32(5):838-50
pubmed: 24927857
Cancers (Basel). 2020 Jun 29;12(7):
pubmed: 32610496
ACS Appl Mater Interfaces. 2020 Mar 18;12(11):12609-12617
pubmed: 32073826
Sci Rep. 2018 Jul 13;8(1):10617
pubmed: 30006510
Sci Rep. 2017 Feb 15;7:42504
pubmed: 28198434
Am J Cancer Res. 2018 Jun 01;8(6):916-931
pubmed: 30034931
Chem Rev. 2021 Mar 24;121(6):3297-3351
pubmed: 32692162
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Pharmacol Ther. 2016 Apr;160:145-58
pubmed: 26899500
J Control Release. 2020 Dec 10;328:454-469
pubmed: 32890553
J Pathol. 2005 Jan;205(2):275-92
pubmed: 15641020
Lancet Oncol. 2017 Jun;18(6):755-769
pubmed: 28479233
Pharm Nanotechnol. 2019;7(1):3-23
pubmed: 30666921
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Cell Death Dis. 2021 Jan 4;12(1):8
pubmed: 33414428
Biomed Pharmacother. 2019 Jun;114:108800
pubmed: 30921705
Breast Cancer Res Treat. 2010 Jan;119(2):283-93
pubmed: 19238537
Front Pharmacol. 2014 May 07;5:93
pubmed: 24847265
EMBO Mol Med. 2019 May;11(5):
pubmed: 31040125
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
Int J Oncol. 2019 Feb;54(2):407-419
pubmed: 30570109
Cancer Res. 1990 Sep 15;50(18):6075-86
pubmed: 1975513
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Oncol. 2019 Nov 22;9:1271
pubmed: 31824851
Semin Cancer Biol. 2021 Nov;76:189-194
pubmed: 33901632
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3505-10
pubmed: 20133674
Asian Pac J Cancer Prev. 2014;15(2):629-35
pubmed: 24568469
Fitoterapia. 2008 Dec;79(7-8):598-601
pubmed: 18664377
Inorg Chem. 2017 Aug 7;56(15):9064-9070
pubmed: 28737381
J Biomed Nanotechnol. 2012 Jun;8(3):508-14
pubmed: 22764421
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
J Biol Chem. 1999 Aug 13;274(33):22932-40
pubmed: 10438458
Sci Rep. 2018 Jun 11;8(1):8867
pubmed: 29891921
Exp Dermatol. 2007 Nov;16(11):899-904
pubmed: 17927572
Cells. 2021 Feb 05;10(2):
pubmed: 33562504
J Nat Prod. 2008 Sep;71(9):1591-4
pubmed: 18778099
Nanomaterials (Basel). 2019 Sep 16;9(9):
pubmed: 31527483
Oncotarget. 2017 Jan 24;8(4):6376-6398
pubmed: 28031527
Dev Cell. 2009 Jan;16(1):35-46
pubmed: 19154717